CTRI/2009/091/000159已完成2 期
An open label, multicenter Phase II study to evaluate efficacy and safety of P276-00 in Indian subjects with recurrent, metastatic or unresectable locally advanced squamous cell carcinoma of head and neck
Piramal Life Sciences Limited0 个研究点目标入组 54 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Age more than or equal to 18 years
- •2.Histologically or cytologically confirmed SCCHN that is recurrent and/or metastatic and judged incurable by surgery and/or radiation therapy. Subjects with locally advanced non?metastatic and/or non-recurrent disease could be enrolled if the tumor is unresectable and has been demonstrated to be refractory to at least one regimen of chemotherapy besides being judged incurable by radiation therapy.
- •3.Measurable disease, defined as at least one unidimensionally measurable lesion >/= 20 mm by conventional techniques or >/=10 mm by spiral computerized tomography (CT) scan or magnetic resonance imaging (MRI)
- •4.Tumor that is accessible to biopsy
- •5.Eastern Cooperative Oncology Group (ECOG) performance status </= 2
- •6.Life expectancy of at least three months
- •7.Hemoglobin >/= 8.0 gm/dL
- •8.Absolute neutrophil count (ANC) >/= 1000/mm3
- •9.Platelet count >/= 50,000/mm3
- •10.Total bilirubin </= 1.5X institutional upper limit of normal (ULN)
- •11.Serum AST </= 3X institutional ULN
- •12.Serum ALT </= 3X institutional ULN
- •13.Serum creatinine </= 1.5X institutional ULN
- •14.Ability to understand and the willingness to sign a written informed consent document (ICD
排除标准
- •1.Nasopharyngeal carcinoma
- •2.Prior treatment with P276-00 or other Cyclin dependent kinase (CDK) targeting agents
- •3.History of allergic reactions attributed to compounds of similar chemical composition to P276-00
- •4.Subjects who have received radiotherapy, chemotherapy or biologic/targeted anticancer agents within 4 weeks prior to Day 1 of study drug administration (6 weeks for nitrosoureas or mitomycin C) or have not recovered from adverse effects of any prior radiotherapy, chemotherapy or biologic/targeted agents
- •5.More than one chemotherapy regimen for the recurrent or metastatic disease
- •6.Subjects who had received any other investigational drug within 1 month or within five half-lives of the other investigational agent, whichever is longer prior to Day 1 of study drug administration
- •7.Subjects with QTc 450 msec on 12?lead standard electrocardiogram (ECG)
- •8.History of unstable angina or myocardial infarction or stroke within previous 6 months
- •9.Subjects with uncontrolled inter-current illness including, but not limited to active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- •10.Subjects known to be suffering from infection with HIV, Tuberculosis, Hepatitis C or Hepatitis B
- •11.Known brain metastasis
- •12.History of prior malignancy except for curatively treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been disease-free for at least 3 years
- •13.Women who are pregnant or lactating
- •14.Women of childbearing potential [defined as sexually mature women who have not undergone hysterectomy or who have not been naturally postmenopausal for at least 24 consecutive months (i.e. who have had menses any time in the preceding 24 consecutive months)] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to study entry (after signing the ICD), during the period of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized
- •15.Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at an unacceptable risk or deems the subject not suitable for participation in the study
研究者
相似试验
招募中
1 期
The study is a Phase 2, open-label, multicenter study to determine the efficacy and safety of Luspatercept (ACE-536) in adults with congenital dyserythropoietic anemia type II (CDA II).Congenital Dyserythropoietic Anemia type II (CDAII)MedDRA version: 21.1Level: PTClassification code 10081457Term: Congenital dyserythropoietic anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-005736-30-ITFOndazione per la Ricerca sulle ANemie ed EMoglobinopatie in ItaliA - For Anemia40
进行中（未招募）
1 期
Study of sebelipase alfa in young children with Lysosomal Acid Lipase Deficiency (LALD).EUCTR2014-000533-22-GBAlexion Pharmaceuticals Inc10
进行中（未招募）
1 期
Study of sebelipase alfa in young children with Lysosomal Acid Lipase Deficiency (LALD).ysosomal Acid Lipase Deficiency (LALD)MedDRA version: 17.0Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850EUCTR2014-000533-22-ITSynageva BioPharma Corp.10
进行中（未招募）
1 期
Study of sebelipase alfa in young children with Lysosomal Acid Lipase Deficiency (LALD).ysosomal Acid Lipase Deficiency (LALD)MedDRA version: 19.1Level: HLTClassification code 10024579Term: Lysosomal storage disordersSystem Organ Class: 100000004850EUCTR2014-000533-22-FIAlexion Pharmaceuticals Inc10
招募中
1 期
Study to evaluate the efficacy and safety of BGB-11417in participants with Waldenström’s MacroglobulinemiaRelapsed/Refractory Waldenström’s MacroglobulinemiaCTIS2023-503235-18-00Beigene Ltd.121